Zura Bio Limited reported second quarter 2026 financial results, announcing a net loss of $26.3 million, or $0.21 per share, compared to $16.0 million in the prior year period. Research and development expenses increased to $20.7 million from $8.7 million, while general and administrative expenses decreased to $8.6 million from $9.4 million. The company holds $205.1 million in cash and cash equivalents as of June 30, 2026, sufficient to fund operations through at least the end of 2028. Clinically, Zura completed enrollment in both Phase 2 studies for its lead candidate tibulizumab: TibuSHIELD in hidradenitis suppurativa enrolled 247 participants with topline data expected in Q4 2026, and TibuSURE in systemic sclerosis enrolled 91 participants with data anticipated in H1 2027. Additionally, Zura plans to initiate a Phase 2 study for tibulizumab in polymyalgia rheumatica by year-end 2026 following constructive FDA feedback. Zura Bio Limited is a clinical-stage biotechnology company developing novel bispecific antibodies for autoimmune and inflammatory diseases.

On June 17, 2026, Zura Bio Limited held its Annual General Meeting of Shareholders. Shareholders approved an amendment and restatement of the Company's 2023 Equity Incentive Plan, which became effective immediately. Additionally, shareholders elected eight directors to the Board and ratified the appointment of WithumSmith+Brown, PC as the independent registered public accounting firm for the fiscal year ending December 31, 2026. Zura Bio is a biotechnology company.